Evidence map›Paper›PMID 38464076›Full record

ArticlebioRxiv : the preprint server for biology2024

cMPL-Based Purification and Depletion of Human Hematopoietic Stem Cells: Implications for Pre-Transplant Conditioning.

Daisuke Araki, Sogun Hong, Nathaniel Linde, Bryan Fisk, Neelam Redekar, Christi Salisbury-Ruf, Allen Krouse, Theresa Engels, Justin Golomb, Pradeep Dagur and 3 more

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

Daisuke ArakiCellular and Molecular Therapeutics Branch, National Heart, Lung and Blood Institute (NHLBI), National Institutes of Health (NIH), Bethesda, MD 20892, USA.ORCID 0000-0001-5937-8882
Sogun HongTranslational Stem Cell Biology Branch, NHLBI, NIH, Bethesda, MD 20892, USA.
Nathaniel LindeTranslational Stem Cell Biology Branch, NHLBI, NIH, Bethesda, MD 20892, USA.
Bryan FiskIntegrated Data Science Services, National Institutes of Allergy and Infectious Diseases, NIH, Bethesda, MD 20892, USA.
Neelam RedekarIntegrated Data Science Services, National Institutes of Allergy and Infectious Diseases, NIH, Bethesda, MD 20892, USA.
Christi Salisbury-RufCellular and Molecular Therapeutics Branch, National Heart, Lung and Blood Institute (NHLBI), National Institutes of Health (NIH), Bethesda, MD 20892, USA.
Allen KrouseTranslational Stem Cell Biology Branch, NHLBI, NIH, Bethesda, MD 20892, USA.
Theresa EngelsTranslational Stem Cell Biology Branch, NHLBI, NIH, Bethesda, MD 20892, USA.
Justin GolombTranslational Stem Cell Biology Branch, NHLBI, NIH, Bethesda, MD 20892, USA.
Pradeep DagurFlow Cytometry Core Facility, NHLBI, NIH, Bethesda, MD 20892, USA.
Diogo M MagnaniNonhuman Primate Reagent Resource, University of Massachusetts Medical School, Worcester, MA 01605, USA.
Zhirui WangDivision of Plastic and Reconstructive Surgery, and Division of Transplant Surgery, Department of Surgery, School of Medicine, University of Colorado Denver, Aurora, CO 80045, USA.
Andre LarochelleCellular and Molecular Therapeutics Branch, National Heart, Lung and Blood Institute (NHLBI), National Institutes of Health (NIH), Bethesda, MD 20892, USA.ORCID 0000-0003-0685-2186
National Institutes of Health · USUniversity of Colorado Denver · USUniversity of Massachusetts Chan Medical School · US

Funding

Regenerative Therapies for Inherited Blood Disorders-Gene therapyZIAHL006172 · NHLBI · NATIONAL HEART, LUNG, AND BLOOD INSTITUTE · PI LAROCHELLE, ANDRE · 2013 to 2025
$13.0M
Investigation of the mechanisms of action of eltrombopagZIAHL006205 · NHLBI · NATIONAL HEART, LUNG, AND BLOOD INSTITUTE · PI LAROCHELLE, ANDRE · 2015 to 2025
$6.8M
Resource CoreP40OD028116 · OD · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI Diogo Magnani · 2020 to 2026
$5.9M
Intramural NIH HHS Z99 HL999999Intramural NIH HHS ZIA HL006172NIH HHS P40 OD028116
6 · The paper itself

Abstract

The transplantation of gene-modified autologous hematopoietic stem and progenitor cells (HSPCs) offers a promising therapeutic approach for hematological and immunological disorders. However, this strategy is often limited by the toxicities associated with traditional conditioning regimens. Antibody-based conditioning strategies targeting cKIT and CD45 antigens have shown potential in mitigating these toxicities, but their long-term safety and efficacy in clinical settings require further validation. In this study, we investigate the thrombopoietin (TPO) receptor, cMPL, as a novel target for conditioning protocols. We demonstrate that high surface expression of cMPL is a hallmark feature of long-term repopulating hematopoietic stem cells (LT-HSCs) within the adult human CD34+ HSPC subset. Targeting the cMPL receptor facilitates the separation of human LT-HSCs from mature progenitors, a delineation not achievable with cKIT. Leveraging this finding, we developed a cMPL-targeting immunotoxin, demonstrating its ability to selectively deplete host cMPL

Identifiers

PMID38464076
PMCPMC10925094
OpenAlexW4392243695

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.